Cargando…

Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea

Background: Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) can cause invasive pneumococcal diseases (IPD), pneumonia, and acute otitis media (AOM). Both the 10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV) and the 13-valent pneumococcal conjugate vaccine (PC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xu-Hao, Leeuwenkamp, Oscar, Oh, Kyu-Bin, Lee, Young Eun, Kim, Chul-Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791581/ https://www.ncbi.nlm.nih.gov/pubmed/29115905 http://dx.doi.org/10.1080/21645515.2017.1362513

Ejemplares similares

Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model
por: Delgleize, Emmanuelle, et al.
Publicado: (2016)

Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy
por: Castiglia, Paolo, et al.
Publicado: (2017)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
por: Izurieta, Patricia, et al.
Publicado: (2021)

A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea
por: Lee, Soon Min, et al.
Publicado: (2018)

Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia
por: Wang, Xiao Jun, et al.
Publicado: (2017)

Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial
por: Dicko, Alassane, et al.
Publicado: (2011)

Effects of Vaccination with 10-Valent Pneumococcal Non-Typeable Haemophilus influenza Protein D Conjugate Vaccine (PHiD-CV) on the Nasopharyngeal Microbiome of Kenyan Toddlers
por: Feazel, Leah M., et al.
Publicado: (2015)

A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand
por: Varghese, Lijoy, et al.
Publicado: (2018)

A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia
por: Lagoubi, Youness, et al.
Publicado: (2022)

Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries
por: Marijam, Alen, et al.
Publicado: (2022)

Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial
por: Tregnaghi, Miguel W., et al.
Publicado: (2014)

Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children
por: Dicko, Alassane, et al.
Publicado: (2013)

10‐valent pneumococcal non‐typeable Haemophilus influenzae protein‐D conjugate vaccine (PHiD‐CV) induces memory B cell responses in healthy Kenyan toddlers
por: Muema, D. M., et al.
Publicado: (2015)

Pneumonia hospitalizations and mortality in children 3 – 24-month-old in Nigeria from 2013 to 2020: Impact of pneumococcal conjugate vaccine ten valent (PHiD-CV-10)
por: Iliya, Jalo, et al.
Publicado: (2023)

Correction: Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial
por: Tregnaghi, Miguel W., et al.
Publicado: (2015)

Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study
por: Iwata, Satoshi, et al.
Publicado: (2015)

A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia
por: Lim, Fong Seng, et al.
Publicado: (2014)

Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D–Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media—A Double-Blind Randomized Clinical Trial in Finland
por: Vesikari, Timo, et al.
Publicado: (2016)

Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children: Booster dose and 2-dose catch-up regimens in the second year of life
por: Odusanya, Olumuyiwa O, et al.
Publicado: (2014)

Serotype changes and antimicrobial nonsusceptibility rates of invasive and non-invasive Streptococcus pneumoniae isolates after implementation of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Bulgaria
por: Setchanova, Lena, et al.
Publicado: (2017)

Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study
por: Dicko, Alassane, et al.
Publicado: (2015)

Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines in children: An open-label, randomized, controlled, non-inferiority trial
por: Falup-Pecurariu, Oana, et al.
Publicado: (2016)

Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children
por: Shiragami, Makoto, et al.
Publicado: (2014)

10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial
por: Oguoma, Victor M, et al.
Publicado: (2020)

phiD12-Like Livestock-Associated Prophages Are Associated With Novel Subpopulations of Streptococcus agalactiae Infecting Neonates
por: Renard, Adélaïde, et al.
Publicado: (2019)

Reply to Farkouh RA et al. Comment on “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus Influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”
por: Shiragami, Makoto, et al.
Publicado: (2015)

Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea
por: Heo, Jung Yeon, et al.
Publicado: (2017)

Summary of WG7 at CKM 2018: "Mixing and $CP$ violation in the $D$ system: $x_D$, $y_D$, $|q/p|_D$, $\phi_D$, and direct $CP$ violation in $D$ decays"
por: Bhardwaj, Vishal, et al.
Publicado: (2019)

1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
por: Kim, Hye-Young, et al.
Publicado: (2020)

Response to Wu et al. — Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong
por: Varghese, Lijoy, et al.
Publicado: (2016)

Cost-effectiveness of lutetium ((177)Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden
por: Palmer, Jayne, et al.
Publicado: (2020)

Impact of national pneumococcal vaccination program on invasive pneumococcal diseases in South Korea
por: Jung, Yeon Haw, et al.
Publicado: (2022)

Recent Trends in Invasive Pneumococcal Disease in Korea in the Post-pneumococcal Vaccine Era
por: Huh, Hee Jae, et al.
Publicado: (2023)

Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea
por: Choi, Eun Hwa, et al.
Publicado: (2011)

Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia
por: Perdrizet, Johnna, et al.
Publicado: (2021)

Urticaria Multiforme Post Pneumococcal Vaccination in an Infant
por: Suggu, Sree R., et al.
Publicado: (2021)

Effectiveness and cost-effectiveness of general immunisation of infants and young children with the heptavalent conjugated pneumococcal vaccine
por: Antony, Katja, et al.
Publicado: (2005)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Early Changes in the Serotype Distribution of Invasive Pneumococcal Isolates from Children after the Introduction of Extended-valent Pneumococcal Conjugate Vaccines in Korea, 2011-2013
por: Cho, Eun Young, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_m0kug2fb8lapi58vvnc46d8135